TKIs are small molecules that target HER2 overexpression and include lapatinib, neratinib, tucatinib and pyrotinib to inhibit the activation of PI3K/Akt and MAPK signaling pathways by competing with ATP for binding to the tyrosine kinase domain of HER2, which prevents cancer progression [156,157,158]. Here, AKT1 is linked to cancer.